



TissueGene, Inc. to Participate in the Buzz of BIO at the 2015 BIO CEO & Investor Conference

Rockville, Md. December 1, 2014 – TissueGene, Inc. is pleased to participate in the [Buzz of BIO Contest](#) for the [2015 BIO CEO & Investor Conference](#). Hosted by the Biotechnology Industry Organization (BIO), the 17th Annual BIO CEO & Investor Conference features leading private and emerging public companies. The meeting will take place February 9-10 at the Waldorf Astoria in New York, NY. During the Buzz of BIO contest, industry leaders will be voting for companies they would like to see present at the conference. The community voting period begins at 9:00:00 AM ET on December 1, 2015 and ends at 5:00:00 PM ET on December 5, 2014 at bio.org/ceobuzzofbiovote.

About TissueGene, Inc.

TissueGene, Inc. is a Maryland-based biopharmaceutical company focused on developing novel regenerative therapies for the treatment of various orthopedic diseases. Founded in 1999, the Company is focused on treatments through the regeneration of damaged cartilage, joints, nerves, and bones. TissueGene's proprietary technology employs a form of cell-mediated therapy to deliver therapeutic proteins to localized areas of damaged tissue. The company is currently developing four product candidates for the regeneration of cartilage (TG-C), bone (TG-B), disc (TG-D), and nerve tissue (TG-N). For more information, please visit <http://www.TissueGene.com>.

About the BIO CEO & INVESTOR Conference

The 17th Annual [BIO CEO & Investor Conference](#) is one of the largest investor conference focused on established and emerging publicly traded and select private biotech companies. Because our mission is to support industry-wide success, we present a broad and unbiased view of investment opportunities. In addition, the BIO CEO & Investor Conference draws business development executives from leading global pharmaceutical and established biotechnology companies.